208 related articles for article (PubMed ID: 37182176)
41. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
42. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
43. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
44. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
Barnes JI; Lin JK; Gupta D; Owens DK; Goldhaber-Fiebert JD; Kunz PL
J Natl Compr Canc Netw; 2020 Sep; 18(9):1200-1209. PubMed ID: 32886901
[TBL] [Abstract][Full Text] [Related]
45. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis.
Zhao M; Pan X; Yin Y; Hu H; Wei J; Bai Z; Tang W
Front Public Health; 2022; 10():869960. PubMed ID: 35493395
[TBL] [Abstract][Full Text] [Related]
46. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
48. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
[TBL] [Abstract][Full Text] [Related]
49. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
50. Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.
Yan J; Li C; Zhang X; Cheng L; Ding R; Zhang L
Front Public Health; 2022; 10():942800. PubMed ID: 35923949
[TBL] [Abstract][Full Text] [Related]
51. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Shi Y; Wan X; Tan C; Li J; Peng L
Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
[TBL] [Abstract][Full Text] [Related]
53. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.
Gourzoulidis G; Maniadakis N; Petrakis D; Souglakos J; Pentheroudakis G; Kourlaba G
J Comp Eff Res; 2019 Feb; 8(3):133-142. PubMed ID: 30547679
[TBL] [Abstract][Full Text] [Related]
54. Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis.
Li L; Yang S; Chen Y; Tian L; He Y; Wu B; Dong D
Front Pharmacol; 2022; 13():891008. PubMed ID: 35721168
[No Abstract] [Full Text] [Related]
55. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
57. Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.
Murray A; Lourenco T; de Verteuil R; Hernandez R; Fraser C; McKinley A; Krukowski Z; Vale L; Grant A
Health Technol Assess; 2006 Nov; 10(45):1-141, iii-iv. PubMed ID: 17083853
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
59. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
